ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

Key Points

• ARS Pharmaceuticals has a “Moderate Buy” consensus rating from six analysts, with four buys, one hold and one sell. The average 12-month price target is $25.00, well above the stock’s reported $4.31 price.
• The company reported a quarterly loss of $0.63 per share, missing the $0.48 consensus estimate, although revenue of $33.66 million exceeded expectations. Analysts anticipate a full-year loss of approximately $1.90 per share.
• ARS Pharmaceuticals develops treatments for severe allergic reactions, led by neffy, an FDA-approved epinephrine nasal spray. Institutional investors and hedge funds own 68.16% of the company’s shares.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $25.00.

SPRY has been the subject of several analyst reports. Leerink Partners set a $15.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, September 8th. Weiss Ratings downgraded ARS Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 17th.

ARS Pharmaceuticals Stock Performance

ARS Pharmaceuticals stock opened at $4.31 on Thursday. The company has a market capitalization of $428.63 million, a price-to-earnings ratio of -1.98 and a beta of 1.05. The company has a debt-to-equity ratio of 13.72, a quick ratio of 3.28 and a current ratio of 3.48. The stock has a fifty day moving average of $5.33 and a two-hundred day moving average of $7.30. ARS Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $13.15.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.15). The business had revenue of $33.66 million for the quarter, compared to analysts' expectations of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. On average, analysts anticipate that ARS Pharmaceuticals will post -1.9 EPS for the current fiscal year.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Bessemer Group Inc. raised its holdings in shares of ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company's stock worth $61,000 after purchasing an additional 7,290 shares in the last quarter. Alpine Woods Capital Investors LLC purchased a new position in ARS Pharmaceuticals during the 1st quarter valued at about $80,000. Syon Capital LLC acquired a new position in ARS Pharmaceuticals in the 2nd quarter valued at approximately $80,000. Allianz Asset Management GmbH acquired a new position in shares of ARS Pharmaceuticals in the second quarter worth $82,000. Finally, Foster & Motley Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 2nd quarter valued at about $118,000. 68.16% of the stock is owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company's lead product is neffy, an epinephrine nasal spray designed to provide emergency treatment for allergic reactions, including anaphylaxis, without requiring an injection.

The U.S. Food and Drug Administration approved neffy in 2024 for adults and children who weigh at least 30 kilograms. The product is intended for use when epinephrine is needed and is designed to address barriers associated with injectable epinephrine, such as needle fear, difficulty with administration, and hesitation to use an auto-injector.

ARS Pharmaceuticals was founded in 2015 and is headquartered in San Mateo, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.